Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

iEV

Phase 2Biologic

SShanghai 6th People's Hospital

iEV is one of 66 biologic programs targeting Cognitive impairment. It is currently in Phase 2.

2

Indications

2

Total Trials

2

Active Trials

65

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cognitive ImpairmentRecruiting

Lateral EpicondylitisRecruiting

Cognitive ImpairmentPhase 2

Recruiting

Lateral EpicondylitisPhase 2

Recruiting

Competition

Competitive Landscape

69 competitors in Cognitive Impairment

#DrugCompanyPhaseTrials

Aricept

Azilect

Marinol

Jazz Pharmaceuticals

Brintellix

Intropin

Avandia

Jazz Pharmaceuticals

Epidiolex

Jazz Pharmaceuticals

Nimotop

AAzurity Pharmaceuticals

Coumadin

Pradaxa

Boehringer Ingelheim

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Lateral Epicondylitis1 trial

Safety and Preliminary Efficacy of iEVs Injection in Treating Lateral Epicondylitis of Humerus

Recruiting·SShanghai 6th People's Hospital·Phase 1/2·NCT07111325·24 enrolled

Cognitive impairment1 trial

Induced Pluripotent Stem Cells-derived Small Extracellular Vesicles May Promote Neurological Function and Improve Cognitive Impairment in Acute Ischemic Stroke Patients

Recruiting·HHongmei Wang·Phase 1/2·NCT07145294·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for iEV. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — iEV compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for iEV. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai 6th People's Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: SShanghai 6th People's Hospital

Related News